Journal
NEURAL REGENERATION RESEARCH
Volume 12, Issue 3, Pages 385-388Publisher
MEDKNOW PUBLICATIONS & MEDIA PVT LTD
DOI: 10.4103/1673-5374.202933
Keywords
spinal cord injury; biomarkers; cerebrospinal fluid; injury severity; neurological recovery
Categories
Funding
- Rick Hansen Institute
- Michael Smith Foundation for Health Research
- Craig Neilsen Foundation
- MITACS
Ask authors/readers for more resources
The evaluation of such novel therapies for acute spinal cord injury in clinical trials is extremely challenging. Our current dependence upon the clinical assessment of neurologic impairment renders many acute SCI patients ineligible for trials because they are not examinable. Furthermore, the difficulty in predicting neurologic recovery based on the early clinical assessment forces investigators to recruit large cohorts to have sufficient power. Biomarkers that objectively classify injury severity and better predict neurologic outcome would be valuable tools for translational research. As such, the objective of the present review was to describe some of the translational challenges in acute spinal cord injury research and examine the potential utility of neurochemical biomarkers found within cerebrospinal fluid and blood. We focus on published efforts to establish biological markers for accurately classifying injury severity and precisely predict neurological outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available